STAT3 and prostate cancer: These compounds inhibited the proliferation of prostate cancer cells by repressing the overexpression of miRNA-372, inhibiting inflammation pathways such as the NF-kappaB-dependent pathway, inducing apoptosis, acting as a poroteasome inhibitor, and inhibiting STAT3 activity.